MetaVia (MTVA) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
The annual meeting is scheduled for June 30, 2025, and will be held virtually, with six key proposals on the agenda, including director elections, auditor ratification, executive compensation, a reverse stock split, approval of share issuance, and potential adjournment to solicit more votes.
The Board unanimously recommends voting in favor of all proposals, emphasizing the importance of shareholder participation.
Forward-looking statements address commercial strategy, regulatory timelines, integration of product candidates, and risks related to stock price and fundraising.
Voting matters and shareholder proposals
Proposal 1: Elect two Class III directors for three-year terms.
Proposal 2: Ratify BDO USA, P.C. as independent auditor for 2025.
Proposal 3: Advisory vote on executive compensation (say-on-pay).
Proposal 4: Approve a reverse stock split at a ratio of 1-for-5 to 1-for-30, at Board discretion.
Proposal 5: Approve issuance of shares equal to or exceeding 20% of outstanding stock upon exercise of pre-funded warrants issued in a private placement.
Proposal 6: Authorize adjournment of the meeting to solicit additional proxies if needed for Proposal 5.
Shareholders may submit proposals for the 2026 meeting between March 2 and April 1, 2026.
Board of directors and corporate governance
The Board consists of seven members, with staggered three-year terms; two Class III directors are up for election.
The Board is chaired by Andrew I. Koven, with the CEO and Chair roles separated.
The company is a "controlled company" under Nasdaq rules due to Dong-A's majority ownership, exempting it from certain governance requirements.
Committees include audit, compensation, and nominating/corporate governance, all with independent directors.
Corporate governance guidelines, code of conduct, insider trading, and compensation recovery policies are in place.
Latest events from MetaVia
- Promising obesity and MASH therapies advance with strong early data and major market potential.MTVA
Investor presentation26 Mar 2026 - Strong clinical progress and improved financials position the pipeline for key 2026 milestones.MTVA
Q4 202526 Mar 2026 - DA-1726 and vanoglipel advance in clinical trials, with key data and partnerships expected this year.MTVA
Emerging Growth Virtual Conference25 Feb 2026 - Biotech seeks $6M via unit offering to fund clinical programs, with significant dilution risk.MTVA
Registration Filing12 Jan 2026 - Biotech seeks $12.8M via unit offering to fund MASH/obesity drug trials amid ongoing losses.MTVA
Registration Filing5 Jan 2026 - 14M shares registered for resale after private placement; biotech faces ongoing losses and key risks.MTVA
Registration Filing16 Dec 2025 - Annual meeting to vote on directors, auditor, reverse split, and major share issuance.MTVA
Proxy Filing2 Dec 2025 - Approval sought for warrant share issuance and potential adjournment, with major dilution possible.MTVA
Proxy Filing2 Dec 2025 - Vote sought on issuing shares for warrant exercise, with major shareholder support and dilution risk.MTVA
Proxy Filing2 Dec 2025